▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are therefore asked to report any suspected adverse reactions via the national reporting system found under 4.8 of the SmPC.
This website was developed by Takeda as part of a commitment made in the Risk Management Plan for Intuniv®
Date of preparation: January 2022
Please note that by selecting this icon you are agreeing to change your previously specified location. Please kindly confirm that you wish to proceed, and you will be redirected accordingly.